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activity (14.4±0.9 nmol/min.mg protein) sustained by reversed
electron ﬂow of the respiratory chain when succinate and ATP were
added. This activity was inhibited by the addition of rotenone (88%),
oligomycin (98%), antimycin (77%) andm-CCCP (93%). NO generation
by ETPH-Mg2+ resulted 0.62±0.03 nmol/min.mg protein in optimal
experimental conditions (0.5 mM MgCl2, 0.3 mM KCN). The mtNOS
activity was still detectable (99%) in the absence of an exogenous
electron donor (NADPH) suggesting that NO production could be
supported by electrons derived from the respiratory chain. Rotenone
inhibited mtNOS activity (86%) supported by reversed electron ﬂow,
but it did not inhibit the activity of isolated nNOS indicating that its
inhibitory effect on NO production by ETPH-Mg2+ is due to an
electron ﬂow inhibition and not to a direct action on mtNOS
structure. The dependence of mtNOS activity on metabolic state and
membrane potential, and the physical interaction among mtNOS,
cytochrome oxidase and complex I proteins, support the hypothesis
that mtNOS could interact with complex I proteins using electrons
derived from the respiratory chain for its enzymatic activity.
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Inhibition of the mitochondrial permeability transition pore (PTP)
has proved to be an effective strategy for preventing oxidative stress-
induced cell death, and the pore represents a viable cellular target for
drugs. Here, we report that inhibition of complex I by rotenone is
more effective at PTP inhibition than cyclosporin A (CsA) in tissues
that express low levels of the CsA mitochondrial target, cyclophilin D
(CypD); and, conversely, that tissues in which rotenone does not
affect the PTP are characterized by high levels of expression of CypD
and sensitivity to CsA. Consistent with a regulatory role of complex I
in the PTP-inhibiting effects of rotenone, the concentrations of the
latter required for PTP inhibition precisely match those required to
inhibit respiration; and a similar effect is seen with the antidiabetic
drug metformin, which partially inhibits complex I. Remarkably (i)
genetic ablation of CypD or its displacement with CsA restored PTP
inhibition by rotenone in tissues that are otherwise resistant to its
effects; and (ii) rotenone did not inhibit the PTP unless phosphate
was present, in striking analogy with the phosphate requirement for
the inhibitory effects of CsA. These results indicate that inhibition of
complex I by rotenone or metformin and displacement of CypD by
CsA affect the PTP through a common mechanism; and that cells can
modulate their PTP response to complex I inhibition by modifying the
expression of CypD, a ﬁnding that has major implications for pore
modulation in vivo.
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SERPINB3 (SB3) is a member of the family of ov-serin-protease
inhibitors overexpressed in epithelial and hepatic tumors. We have
found that a fraction of SB3 is located inmitochondria of hepatoma cells.
In order to understand whether the mitochondrial location of SB3 is
somehow connected to biological traits relevant to the neoplastic
phenotype, we have addressed the possibility that SB3 is part of the
anti-apoptotic machinery that hallmarks most tumor types. In partic-
ular, inhibition of the mitochondrial permeability transition pore (PTP)
constitutes a point of no-return in cell commitment to death, and its
inhibition is believed to play a primary role in tumor cell survival and
resistance to anticancer drugs.
We have found that stable transfection with either the human
wild type SB3 or the protease-dead DH-SB3 confers protection to
death induced in hepatoma cells either with the ﬁrst-line chemo-
therapeutic Cisplatin or with the PTP inducer EM20-25. Treatment
with the antioxidant compound N-acetyl cysteine could abrogate
death induction, and SB3-expressing cells show lower ROS levels both
in basal conditions and after EM20-25 treatment. Notably, we observe
that SB3 co-immunoprecipitates with respiratory chain Complex I,
one of the major sites of superoxide production in cells, and that this
interaction results in inhibition of Complex I activity.
Taken together, these results indicate that SB3 protects hepatoma
cells from death induced by oxidative stress through down-modulation
of Complex I and the ensuing PTP desensitization, paving the way for
the identiﬁcation of novel anti-neoplastic strategies.
doi:10.1016/j.bbabio.2012.06.151
6P12
Complex I deﬁciency associated to mitochondrial DNA mutations
in type I endometrial carcinoma
Antonella Cormio1, Flora Guerra2, Giuseppe Gasparre2,
Francesca Amati3, Gennaro Cormio4, Luigi Selvaggi4,
Anna Maria Sardanelli3, Maria Nicola Gadaleta1,5
1Dept. of Biosciences, Biotechnologies and Pharmacological Sciences,
University of Bari, Italy
2Dept. of Medicine and Surgery, Medical Genetics Unit, University
Hospital, S.Orsola-Malpighi, Bologna, Italy
3Dept. of Basic Medical Sciences, University of Bari, Italy
4Dept. Gynecol., Obstet. & Neonatology, University of Bari, Italy
5CNR Institute of Biomembranes and Bioenergetics, Bari, Italy
E-mail: antonella.cormio@uniba.it
Endometrial carcinoma (EC) is a common neoplasia of the female
genital tract. This cancer may be grouped into two subsets, namely
Abstracts S53
